Research programme: synthetic biology therapeutics - Synlogic

Drug Profile

Research programme: synthetic biology therapeutics - Synlogic

Alternative Names: SYN-MSUD; SYN-PKU; SYNB 1618; SYNB1010; Synthetic Biotic™ - Synlogic

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synlogic
  • Developer AbbVie; Synlogic
  • Class Probiotics
  • Mechanism of Action Ammonia scavengers; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatic encephalopathy; Inborn error metabolic disorders; Phenylketonuria
  • Research Acidaemia; Cancer; Inflammatory bowel diseases; Maple syrup urine disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 24 Oct 2017 SYNB 1618 receives Orphan Drug status for Phenylketonuria in USA
  • 24 Oct 2017 Synlogic plans to file an investigational new drug application (IND) with the FDA for SYN B1618 for the treatment of Phenylketonuria in early 2018
  • 07 Sep 2017 Preclinical trials in Inborn error metabolic disorders in USA (PO), before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top